- Pasithea Therapeutics Corp KTTA has initiated a new chemical entity development program and named Evotec SE EVOTF its research partner.
- No deal terms were disclosed.
- Pasithea aims to advance small molecule therapeutics with a focus on a specific neuroinflammatory pathway implicated in the neurobiology of depression and schizophrenia," stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
- Price Action: KTTA shares closed 1.50% lower at $2.62 on Friday.
Loading...
Loading...
EVOTFEvotec SE
Not Available-%
Edge Rankings
Momentum
Not Available
Growth
Not Available
Quality
Not Available
Value
Not Available
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
